Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

Berlin: Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company, have announced that they have entered into an ...

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...

Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...

Bayer and Kumquat Biosciences have entered an exclusive global license and collaboration to develop and commercialize Kumquat ...

Dr. Zev Wainberg of UCLA recently spoke with CURE about trial results concerning the cancer vaccine ELI-002 2P.

An 'off-the-shelf' vaccine may help prevent or delay cancer recurrence in people with hard-to-treat colorectal or pancreatic ...

New clinical data reveals promising efficacy of VS-7375, a KRAS G12D inhibitor, in advanced lung cancer, highlighting its ...

New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.

In an early trial, a one-size-fits-all vaccine showed promise in preventing hard-to-treat pancreatic cancers from coming back ...

AstraZeneca’s recent clinical study update focuses on evaluating the efficacy and safety of Selumetinib in combination with Docetaxel for patients with KRAS mutation-positive locally advanced or ...

Scientists have uncovered dementia-like behavior in pancreas cells at risk of turning into cancer. The findings provide clues ...